Leflunomide is a novel immunomodulatory drug representing a new small molecule class of substances which are structurally unrelated to previously described immunomodulatory/immunosuppressive compounds. The effect of leflunomide on the cell cycle of Succharomyces cerevisiue was investigated to elucidate the molecular mechanism of its action in eukaryotic organisms. When yeast cells were treated with leflunomide, unbudded cells were accumulated, suggesting that leflunomide may arrest the cell cycle in the G1 phase. When leflunomide-treated cells were subjected to heat shock treatment, the cells became resistant to heat shock treatment, implying that leflunomide-mediated block to cell division results in entry from the proliferative cycle into the alternative developmental Go phase.
Introduction
Leflunomide, an isoxazol derivative, is a novel anti-inflammatory and immunosuppressive agent that has been shown to be effective in preventing and treating autoimmune diseases in animals and organ transplantation rejection ([l] for review). Many of the immunosuppressive effects of leflunomide can be attributed to its inhibitory effect on the activity of many cytokines, most likely through receptor expression and signal transduction.
Interference with the activity of IL-2 and IL-4 and consequent interference of cytotoxic T-cell formation may explain the inhibition of transplantation rejection. In vitro investigations concerning its mode of action also demonstrated that leflunomide mediates its effects, at least in part, by inhibiting the cellular proliferation of a variety of cultured cell lines as well as primary murine and human lymphocytes [l] . These data suggest that leflunomide might interfere with a common mechanism leading to cell division [1, 2] .
The immunosuppressants cyclosporin A (CsA), FK506, and rapamycin inhibit the intermediate steps in signal transduction leading to T-cell activation. CsA and FK506 block the activation of quiescent T cells (Go to G1 transition) by interfering with the T-cell receptor-mediated signal transduction pathway [3, 4] . Rapamycin inhibits subsequent G1 to S progression by blocking the response to the lymphokine IL-2. The action of the immunosuppressants is dependent on the formation of a complex with intracellular receptors termed immunophilins.
The budding yeast, Saccharomyces cerevisiae, is a model eukaryotic organism amenable to the investi-gation of complex cellular processes like cell division, sexual differentiation and signal transduction. In yeast, CsA and FK506 inhibit recovery from cr-mating factor arrest through inhibition of calcineulin, a pathway strikingly similar to that involved in the inhibition of T-cell activation [5, 6] . Rapamycin arrests the S. cerevisiae cell cycle in the G1 phase by binding to a highly conserved FK506 binding protein [7, 8] and then by inhibiting TORl, the yeast homolog of phosphatidylinositol-3-phosphate kinase 191. In the present work, the effect of leflunomide on the cell growth of Succharomyces cerevisiae was investigated to elucidate the molecular mechanism of action of leflunomide in eukaryotic organisms and to determine whether leflunomide blocks a specific step of the cell cycle.
Materials and methods

Yeast strains and media S. cerevisiae strains XF91 -IS (MATa ura3 leu2 hisl) and DH17-IC
(MATa ura3 leu2 @I) were used in this study. YEPD (2% glucose, 2% peptone, 1% yeast extract) rich medium and SD (2% glucose. 0.67% yeast nitrogen base without amino acids) minimal medium supplemented with appropriate nutrients were used for cultivation of yeast cells. Growth and manipulation were performed according to the standard procedures [lo] . Leflunomide ( Fig. 1 ) was prepared as a stock solution (20 mg/ml in EtOH).
Isolation oj'a mutant hypersensitive to lejlunomide
Strain XF91-1 B was cultured in YEPD and then mutagenized with 1% ethylmethane sulfonate (EMS) for 60 min at 30°C as described previously [l 11. The cells were spread on YEPD plates, incubated at 30°C for 2 days and replica-plated on SD supplemented with appropriate nutrients containing leflunomide (50 Wml).
Heat shock sensitivity test
Yeast cells were grown in YEPD at 30°C overnight. Cells were then transferred to fresh YEPD in the presence or absence of leflunomide or a-mating factor. After incubation, cells were subjected to 5 min of heat shock at 54°C quick cooling on ice and plating on YEPD plate after serial dilutions to determine viable cell number.
Results
Inhibition of' S. cerevisiae cell growth by ltfhmomide
To ascertain whether yeast cells are susceptible to leflunomide, laboratory strains of S. cerevisiae were transferred to rich medium containing various amount of leflunomide and their growth was observed. As shown in Fig. 2 , strain XF91-1B was sensitive to leflunomide at a concentration of more than 100 ng/ml.
Isolation of a mutant hypersensitive to lejhmomide
As a first step to clarify the response of S. cerevisiae cells to leflunomide, yeast mutants which had became hypersensitive to leflunomide were isolated. XF91-1B was mutagenized with EMS as described in Section 2, and replica-plated on minimal medium containing leflunomide (50 ng/ml). After replica-plating of 2 X 10' independent colonies, a mutant strain was isolated. Genetic analysis indicated that a single recessive mutation was associated with the hypersensitivity to leflunomide; this was designated lfsl for leflunomide hypersensitivity. A lfsl mutant could not griw in the presence of leflunomide (50 yg/ml) (Fig. 2) . 
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LFSl+ Ifsl- Fig. 2 . Effect of leflunomide on the growth of S. cerevisiae. The strains XF91-IB (LFSl+) and DH17-1C (IfsI-) were transferred to YEPD plates containing leflunomide at 0, 50, or 100 &ml and incubated for 2 days at 3O"C, followed by photography.
Arrest of S. cerevisiae cell cycle by leflunomide
A leflunomide-hypersensitive segregant was constructed by tetrad dissection and its response to leflunomide was observed. As shown in Fig. 3 , DH17-1C did not grow in rich medium in the presence of leflunomide, and unbudded cells were accumulated, suggesting that cells are arrested at the G1 phase of the cell cycle.
Heat shock resistance of leflunomide-treated yeast cells
It is well known that when yeast cells enter into the GO phase, they become resistant to heat shock treatment. To clarify the point at which yeast cells are arrested, leflunomide-treated cells were subjected to heat shock treatment and cells that had survived were analyzed. Table 1 shows that leflunomide-treated yeast cells became resistant to a 5-min heat shock treatment, suggesting that leflunomide-treated cells were at the Gs phase of the cell cycle.
Discussion
In this study, I have demonstrated that S. cerevisiae cells are susceptible to leflunomide and cell divi- .0 x 104 (0.4%) 4.9 x 10" (OX%,) I. I x lOti (24%) ---~.-_--Strain DHl7-IC (@I -) grown exponentially in YEPD at 30°C was cultured in YEPD containing leflunomide (50 &ml) or a-mating factor (8.5 pg/ml) for 4 h at 30°C. The drug-treated cells were then subjected to 5 min heat shock at 54"C, followed by quick cooling in ice/water.
The treated cell suspensions were diluted and spread on YEPD. Survival ratios are given in parentheses.
sion is arrested in the G1 phase of the cell cycle in response to this drug. Two lines of evidence suggest that lefunomide may block the transition from the G,> to GI phase of the ceil cycle: (I) accumulation of unbudd~d cells with morpho~ogi~lly unchanged shapes; (2) heat shock resistance. These phenotypes are in striking contrast to those cells treated with a-mating factor which are heat shock sensitive.
The striking similarity between the mode of action of the immunosuppressants CsA, FK506, and rapamycin in yeast cells and in lymphocytes provides several means to elucidate the conserved molecular mechanism involved and to determine the components of drug-sensitive regulatory networks [5] . Leffunomide blocks the cell cycle in yeast cells and in lymphocytes, suggesting that an evoIutionariIy conserved, ieflunomide-sensitive pathway may regulate the cell cycle both in yeast and in lymphocytes.
Leflunomide was reported to inhibit the epidermal growth factor (EGF) receptor tyrosine kinase activity. Leflunomide inhibits both the autophosphorylation of the EGF receptor in intact cells and the tyrosine kinase activity of the purified EGE receptor [12] . Leflunomide also inhibits Ihe Src famiiy (~56"" and ~59~v") of tyrosine kinases, enzymes that are associated with transduction of many growth factor receptor signals, including IL-2, IL-3. and IL-4, but not IL-1 [I 31 . A possible mechanism of leflunomide action in yeast cells is that leflunomide might inhibit a tyrosine kinase which is essential for cell growth, especially for transition from the Go to the G1 phase of the cell cycle, although any receptor-type tyrosine kinase has not been identified so far in S. cerevisiae. On the other hand, S. cerevisiue has several proteintyrosine kinases 1141. One of them would be a candidate for the target of leflunomide.
The present study provides a powerful system in which a @I supersensitive mutant can be used as a host strain for molecular cloning of a gene which encodes a target molecule and also confers leflunomide resistance in multicopy plasmid.
Further genetic analysis of the responsiveness of S. ~erevi.~iff~ will give a clue to identify the target(s) of leflunomide and give insight into the molecular mechanism of the action of leflunomide on T-cell and B-ceil activation and differentiation during the immune response.
